Complete Engineering Guide: Selecting and Implementing High-Speed Pen Injector Final Assembly Systems

A Technical White Paper by DROFEN MACHINERY EQUIPMENT CO., LTD

Author: Jordan Xu, Managing Director

Final assembly represents the most critical and highest-risk stage in injection pen manufacturing. Unlike pre-assembly - where a rejected unit costs only the plastic components - a rejection during final assembly means the loss of an entire pre-filled drug cartridge, potentially worth several dollars per unit. When multiplied across millions of annual units, even a fraction of a percentage point in rejection rate translates into substantial financial and regulatory consequences.

 

these specific high-value risks in 84 ppm final assembly platforms. Our engineering team identified that the cartridge press-fit operation is the single most critical point of failure in the entire manufacturing process. Consequently, this guide explains how we engineered a modular 2-cell architecture (24 stations) around this critical node-integrating real-time Kistler force-displacement curve monitoring to prevent cartridge micro-cracks, and multi-point Keyence LVDT verification to guarantee dose accuracy. It also outlines the RFID-based unit-level traceability across 42 pallets and the 21 CFR Part 11 compliant validation framework necessary for commercial release.

 

The document is intended for pharmaceutical engineers, CDMO operations directors, and equipment procurement teams evaluating automated final assembly solutions for insulin pens, GLP-1 delivery devices, and similar cartridge-based injection systems.

The global injection pen market is experiencing unprecedented growth driven by the rapid expansion of GLP-1 receptor agonist therapies. Semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and tirzepatide (Mounjaro/Zepbound) have collectively created demand for billions of additional pen injector units annually. This demand surge has exposed a critical bottleneck in the pharmaceutical manufacturing supply chain: final assembly capacity.

 

Unlike fill-finish operations - where established CDMOs maintain significant installed capacity for vial and syringe filling - pen injector final assembly remains a specialized capability concentrated among a small number of equipment suppliers and contract manufacturers. The complexity of integrating a pre-filled drug cartridge with a multi-component mechanical dosing device, combined with the stringent regulatory requirements for 100% in-process inspection, means that final assembly lines cannot be rapidly deployed using general-purpose automation equipment.

 

This capacity constraint is particularly acute for CDMOs serving biosimilar manufacturers entering the GLP-1 space. These organizations need to establish pen injector manufacturing capability rapidly, but face lead times of 8–12 months for custom final assembly equipment - assuming they can identify a qualified equipment supplier with available engineering capacity. The situation is further complicated by the fact that many CDMOs lack in-house pen device expertise, making them dependent on their equipment supplier for both device design and manufacturing process development.

 

For pharmaceutical engineers and CDMO operations directors evaluating final assembly solutions, understanding the engineering principles behind high-speed pen assembly is essential for making informed equipment selection decisions. This white paper provides that engineering foundation.

In the injection pen manufacturing process, the production chain is typically divided into three major stages: component molding, pre-assembly (mechanical pen body construction), and final assembly (integration of the pre-filled drug cartridge with the assembled pen mechanism). While all three stages demand precision, final assembly carries a fundamentally different risk profile.

 

During pre-assembly, the materials being handled are injection-molded plastic components - housings, cover plates, push plates, rotors, and threaded sleeves. If a unit fails quality inspection at any pre-assembly station, the cost of rejection is limited to the raw material value of those plastic parts, typically measured in cents.

 

Final assembly operates under entirely different economics. At this stage, the pen body has already been fully assembled and verified, and a pre-filled drug cartridge - containing insulin, semaglutide, liraglutide, or another high-value biologic - is being integrated into the device. A single rejected unit at final assembly means the loss of not only the pen body but also the drug product contained within the cartridge. For GLP-1 receptor agonists, the drug value per cartridge can exceed $5–$10 at manufacturing cost, making every unnecessary rejection a direct hit to production economics.

 

This asymmetry in rejection cost creates a fundamental engineering requirement: the final assembly system must achieve the highest possible first-pass yield while simultaneously maintaining 100% inspection coverage. There is no acceptable trade-off between speed and quality at this stage.

DROFEN's final assembly platform is built on a compact 2-cell architecture with peripheral handling systems. Rather than constructing a single monolithic machine with all stations arranged in one continuous line, the system divides the assembly process into two functionally distinct cells - each containing 12 stations - connected by a pallet-based transfer system.

This modular approach delivers several critical advantages. First, it enables parallel development and testing - each cell can be designed, built, and validated independently before integration, compressing the overall project timeline. Second, it provides maintenance isolation - if one cell requires intervention, operators can address the issue with minimal impact on the overall system. Third, the compact 2-cell footprint minimizes cleanroom floor space requirements while maintaining full production capacity.

 

The complete final assembly system consists of the following functional units:

 

Additionally, the system includes dedicated feeding peripherals: vibratory bowl feeders for cartridge holders and pen caps, and a conveyor-based feeding system for pre-filled cartridges.

 

The transfer system operates with 42 pallets, each equipped with an RFID identification chip. Every pallet carries 6 nest positions in a 2-up configuration, meaning each pallet cycle produces two finished pens simultaneously.

 

At the entry point of each cell, the RFID tag is read to identify the pallet and retrieve its complete status history. Every station records its process result against the specific pallet and nest position. This architecture ensures complete unit-level traceability - from incoming component through every assembly and inspection operation to the finished device. If any quality event occurs, the system can immediately identify which specific nest on which specific pallet was affected, and trace the complete processing history of that unit.

 

Note: This configuration represents one variant of DROFEN's final assembly platform. Higher-throughput configurations are available, with proven capability up to 160 pens per minute.

The first station in Cell 1 performs comprehensive incoming verification of the pre-assembled pen mechanism. This station integrates multiple inspection technologies in a single index cycle: presence sensors confirm that a mechanism exists in each nest position; a vision system performs dose button color verification and variant printing inspection; and a Keyence LVDT measurement system contacts the mechanism rod to establish the incoming baseline for the dosing mechanism position.

 

Any unit that fails presence detection, vision inspection, or LVDT measurement is immediately flagged as BAD and will not be processed at any subsequent station.

 

The dosing mechanism must be "primed" before final assembly - a process that involves rotating the dosing sleeve through its full travel range multiple times to verify smooth operation and establish the correct mechanical engagement. DROFEN's system performs this through a 4-cycle pre-primming sequence, with alternating pre-primming and reset stations.

 

At each pre-primming station, a servo motor rotates the dosing sleeve to a defined index count while a second servo motor controls the vertical positioning of the gripper. The subsequent reset station presses the dose button to return the mechanism to the "0" position, verified by a position sensor. This four-cycle sequence ensures that the dosing mechanism has been exercised through its complete range of motion and returns reliably to zero position before the cartridge is integrated.

 

Cartridge holders are fed from a dedicated vibratory bowl feeder through a linear track to an escapement mechanism. A vision system detects the printing orientation, and servo-driven rotary units rotate the part to the correct angular position before cam-driven placement onto the pallet.

 

Pen caps are loaded through a second vibratory bowl feeder with similar orientation correction. Both bowl feeders provide approximately 30 minutes of autonomous operation at full capacity before requiring refill, with low-level sensors alerting the operator when replenishment is needed.

The pre-filled drug cartridge - the highest-value component in the assembly - is fed through a conveyor-based system rather than vibratory feeding. This design choice reflects the sensitivity of the pre-filled cartridge: vibratory feeding could potentially damage the cartridge seal or affect drug product integrity. The conveyor system gently transports cartridges to an escapement mechanism, where rotary grippers invert and position the cartridges onto the cartridge holders already seated on the pallet.

 

This is the most critical operation in the entire final assembly system.

The pressing operation is performed by a servo-driven press unit that provides controlled, repeatable descent with precise speed and force profiles. The instrumentation suite includes:

 

Operating Principle: The servo press descends at a controlled rate while the Kistler load cell continuously measures the applied force. Simultaneously, the Balluff linear transducer tracks the displacement of the press head. The Kistler force monitor captures the complete force-displacement curve - plotting force (N) against displacement (mm) throughout the entire insertion stroke.

 

This curve is evaluated in real-time against a pre-defined acceptance envelope established during process validation. A conforming press operation must produce a curve that remains within the acceptance envelope throughout the entire stroke. Any deviation triggers an immediate NG classification:

 

Why Force-Displacement Curves, Not Just Peak Force: A simple peak-force threshold would miss numerous failure modes. A pen housing with an internal crack may show normal peak force but an abnormal curve shape - a sudden force drop mid-stroke followed by recovery. A cartridge holder with flash from the injection molding process may show a force spike at a specific displacement point but normal peak force. Only the complete force-displacement curve captures these subtle but critical defects.

 

The force-displacement curve for every single unit is recorded and stored in the electronic batch record system. This 100% inspection data provides complete traceability for regulatory submissions and supports statistical process control.

 

The system maintains station-level bad-part counters. If consecutive NG events occur at the same station, the system triggers an alarm and halts the cell for operator investigation. This consecutive-NG logic serves as an early warning system for process drift: a single NG may represent normal statistical variation in incoming component dimensions, but consecutive NGs at the same station indicate a systematic issue - such as a batch of cartridge holders with out-of-specification dimensions, or a worn press tool requiring replacement.

 

The final station performs two operations in sequence. First, a pick-and-place unit transfers the assembled mechanism + cartridge holder assembly and inserts it into the pen cap - completing the physical assembly of the finished injection pen. Second, a vision system performs a final "0" position check, verifying that the dosing window displays the correct zero marking and that the overall assembly alignment meets cosmetic specifications.

 

The system implements conservative event-handling logic for any condition that could compromise product quality:

A UPS is installed in the control cabinet to protect data integrity during power failure events - ensuring that batch records and audit trails are properly saved before system shutdown.

The pre-filled drug cartridge is simultaneously the highest-value and most fragile component in the final assembly process. Unlike injection-molded plastic parts - which tolerate vibration, minor impacts, and wide temperature ranges - a pre-filled cartridge contains a biologic drug product sealed under controlled conditions. The engineering decisions around how this component is stored, transported, and inserted into the pen body have direct consequences for both product quality and patient safety.

 

Vibratory bowl feeders are the standard solution for feeding small components in high-speed assembly systems. They are used extensively in DROFEN's final assembly platform for cartridge holders, pen caps, and other plastic components. However, pre-filled cartridges cannot be fed through vibratory systems for several critical reasons.

 

First, the cartridge contains a rubber plunger stopper that forms the primary container closure. Repeated vibration and part-to-part contact inside a bowl feeder can generate particulate contamination from the rubber surface - introducing sub-visible particles that would fail container closure integrity testing. Second, the cartridge crimp cap (typically aluminum) is susceptible to cosmetic damage from the tumbling action inside a vibratory bowl. While cosmetic damage does not necessarily affect functionality, it creates a visual defect that will be flagged during downstream labeling inspection, resulting in unnecessary rejections. Third, for temperature-sensitive biologics such as certain GLP-1 formulations, the heat generated by vibratory feeding (from friction between parts and bowl surface) can create localized temperature excursions that compromise drug stability.

 

For these reasons, DROFEN's final assembly system uses a dedicated conveyor-based cartridge feeding system. Cartridges are loaded in their original tray packaging (maintaining the cold chain orientation from fill-finish), and individual cartridges are singulated through a gentle escapement mechanism that eliminates part-to-part contact throughout the entire feeding process.

 

Pre-filled cartridges arrive from the fill-finish line in a specific orientation - typically with the crimp cap (needle end) facing upward. However, the final assembly process requires the cartridge to be inserted into the pen body with the crimp cap facing downward (toward the needle hub). This means every cartridge must be inverted 180° during the feeding process.

 

This inversion operation must be performed with extreme care. Rapid inversion can create air bubbles in the drug product - particularly problematic for protein-based biologics where foaming can cause aggregation and loss of potency. DROFEN's rotary gripper system performs the inversion at a controlled angular velocity, with the rotation profile optimized to minimize fluid disturbance inside the cartridge.

 

Glass cartridges for injection pens are internally siliconized to ensure smooth plunger glide force during drug delivery. However, this silicone oil coating creates a handling challenge during automated assembly: if the external surface of the cartridge becomes contaminated with silicone oil (from handling equipment or from oil migration during storage), it can interfere with the adhesive bond between the cartridge and the cartridge holder, potentially causing the cartridge to loosen during patient use.

 

The feeding and gripping systems must be designed to contact only designated gripping zones on the cartridge surface, avoiding any contact with the barrel area where silicone contamination could affect the holder-to-cartridge interface. DROFEN's gripper design contacts only the cartridge shoulder and crimp cap - areas that do not participate in the adhesive or interference-fit retention mechanism.

 

Before the press-fit operation, the system must verify that a cartridge is actually present in the cartridge holder and that it is correctly seated. A missing or incorrectly positioned cartridge that enters the press station would result in either a false-good (pen assembled without drug product) or equipment damage (press force applied to an empty holder).

 

DROFEN's system performs this verification through a combination of Keyence LVDT measurement (confirming the cartridge plug position relative to the holder shoulder) and a vision system (confirming cartridge presence and correct orientation). This dual-verification approach ensures that no empty or misaligned cartridge proceeds to the critical press-fit operation.

Unlike force monitoring (which detects defects during assembly operations), LVDT measurements verify dimensional conformance at critical process transitions. DROFEN's final assembly system incorporates Keyence high-precision LVDT checkpoints at four stages:

 

This multi-point strategy creates a progressive quality assurance chain. If the incoming measurement is within specification but the post-pre-primming measurement shows deviation, the system immediately identifies that the pre-primming process has caused an issue - enabling targeted investigation rather than a general line shutdown.

A common question from engineers evaluating high-speed assembly systems is why mechanical cam-driven pick-and-place mechanisms are preferred over servo-driven robotic arms for primary material handling. The answer lies in the fundamental physics of high-speed cyclic operation.

 

At 42 cycles per minute, each pick-and-place operation must complete a full sequence - extend, grip, retract, transfer, extend, release, retract - within approximately 1.4 seconds. While servo-driven systems can achieve this speed, mechanical cam profiles provide inherently repeatable motion paths. The cam geometry physically defines the position, velocity, and acceleration at every point in the cycle. There is no servo tuning to drift, no encoder feedback to lose, and no gearbox backlash to accumulate over millions of cycles.

 

DROFEN employs a hybrid approach: mechanical cams for repeatable high-speed transport, and servo motors specifically where controlled rotation or variable force is required - pre-primming, final dosing sleeve rotation, and the critical press-fit operation. This combination delivers the reliability of fixed mechanical systems with the flexibility needed for process-critical operations.

 

The choice between cam-driven and servo-driven material handling also has significant long-term maintenance implications. Mechanical cam systems require periodic lubrication and eventual cam follower replacement (typically every 18–24 months at continuous high-speed operation), but these are predictable, scheduled maintenance activities. Servo-driven systems, by contrast, may experience intermittent positioning faults that are difficult to diagnose - encoder drift, gearbox wear, or cable fatigue can produce subtle position errors that manifest as occasional assembly defects rather than obvious mechanical failures.

 

For pharmaceutical manufacturing environments where unplanned downtime directly impacts batch scheduling and regulatory commitments, the predictability of cam-based maintenance is a significant operational advantage. Maintenance teams can schedule cam follower replacements during planned shutdowns without risk of unexpected mid-batch failures.

 

High-speed cam mechanisms generate characteristic vibration signatures that must be managed in cleanroom environments. DROFEN's cam systems are designed with optimized cam profiles that minimize acceleration discontinuities - reducing both mechanical shock loads and transmitted vibration. The cam profiles use modified trapezoidal or polynomial motion curves rather than simple harmonic profiles, providing smoother acceleration transitions at high cycle rates.

 

This vibration management is particularly important for the stations adjacent to the cartridge handling area, where excessive vibration could affect the pre-filled cartridge during the brief period between loading and press-fit completion.

The system is governed by a Siemens industrial PLC with an Advantech industrial panel PC providing a bilingual (Chinese/English) operator interface. The control system manages real-time machine control, pallet tracking, part status management, and station interlock logic.

 

The control system is designed for full compliance with FDA 21 CFR Part 11 and EU Annex 11 requirements:

 

Audit Trail: Every parameter change, recipe modification, and operator action is recorded with timestamp, logged-in user identification, initial value, new value, and user comment. Audit trail records are stored on both the HMI and Line PC, exported as non-modifiable PDF reports, and cannot be deleted or altered.

 

User Management: Hierarchical access control with a minimum of 3 user levels. Passwords require alphanumeric characters with configurable mandatory change cycles and automatic session logout.

 

Data Integrity: Production data is stored in database format on the Line PC. Data can be backed up and copied to USB storage for archival.

Electronic Batch Record (EBR): The system generates a comprehensive electronic batch record for each production run. The EBR includes: total parts processed, parts passed, parts rejected (categorized by rejection reason and station), force-displacement curves for every pressed unit, all LVDT measurements, vision inspection results, alarm history with timestamps and operator responses, and recipe parameters active during the run. This EBR can be exported in PDF format for inclusion in the batch release documentation package.

 

The HMI implements a structured alarm management system designed to minimize operator response time and reduce the risk of incorrect interventions. Alarms are categorized into three severity levels:

 

Each alarm includes a plain-language description of the condition, the affected station, and a suggested corrective action. This structured approach reduces mean-time-to-repair (MTTR) by guiding operators directly to the root cause rather than requiring them to diagnose the issue from a generic error code.

 

The recipe management system stores all process-critical parameters for each pen variant in a validated, version-controlled recipe structure. Recipe parameters include: pre-primming cycle count and rotation index, LVDT acceptance ranges for each measurement point, force-displacement envelope boundaries, press speed and stroke distance, vision inspection reference images and tolerance windows, and reject station sorting logic.

 

Recipe changes require supervisor-level access and are fully captured in the audit trail. The system enforces a "recipe lock" during production - preventing any parameter modification while a batch is active. This ensures that every unit within a batch is processed under identical, documented conditions.

 

DROFEN delivers every final assembly system with a comprehensive validation documentation package structured according to the GAMP 5 V-model lifecycle:

 

The final assembly platform accommodates cartridge-based injection pens across the full range of current and emerging therapies:

The HMI supports multiple product recipes. Changeover between variants involves selecting the target recipe on the HMI and switching the press station gripper via a slider cylinder position switch. Mechanical changeover is minimized by the slider cylinder design - the servo press module switches position pneumatically rather than requiring manual tool changes for most variant transitions.

Pen injector final assembly typically operates in an ISO 8 (Class 100,000) or ISO 7 (Class 10,000) cleanroom environment, depending on the customer's quality risk assessment and the specific drug product being handled. The equipment design must accommodate these environmental constraints without compromising production efficiency.

 

DROFEN's final assembly platform is designed with cleanroom operation as a primary requirement rather than an afterthought. All external surfaces are constructed from stainless steel (SUS304) or anodized aluminum with smooth, wipe-down-compatible finishes. Cable routing is fully enclosed within the machine frame, eliminating exposed cable trays that accumulate particulate. Pneumatic exhaust is routed through centralized manifolds with filtration, preventing compressed air discharge from introducing particles into the cleanroom environment.

The machine footprint is optimized to maintain adequate clearance from cleanroom walls for airflow circulation. The 2-cell architecture provides a particularly compact footprint relative to single-line configurations of equivalent throughput - a critical advantage in cleanroom environments where floor space carries a significant cost premium (typically $2,000–$5,000 per square meter for ISO 7 construction).

 

High-speed mechanical assembly inherently generates particles from component contact, cam mechanism operation, and vibratory feeding. The system manages particle generation through several design strategies: vibratory bowl feeders are enclosed with HEPA-filtered extraction; cam mechanism lubrication uses cleanroom-compatible greases with low outgassing characteristics; and the reject station incorporates local extraction to prevent rejected parts from contaminating the production path.

 

Additionally, the pallet transfer system operates on precision linear guides with sealed bearings, minimizing metal-to-metal particle generation from the transport mechanism itself. The RFID read/write heads are non-contact devices that generate zero particles during operation.

 

With only 3 operators required for full production operation, the system minimizes human presence in the cleanroom - reducing both contamination risk and gowning costs. Operator interaction points (material loading, HMI access, reject bin removal) are consolidated on the front face of the machine, allowing operators to perform all routine activities without reaching over or behind the equipment. This ergonomic design reduces the frequency of gown contamination events that would require re-gowning.

The final assembly system does not operate in isolation. Finished pens exiting the good-parts unloading station (P2) must be transferred to downstream labeling and secondary packaging operations. The interface between final assembly and downstream equipment is a critical design consideration that affects overall line efficiency.

 

The P2 unloading station transfers conforming pens onto an output conveyor that serves as a buffer between the assembly system and the downstream labeling machine. This buffer provides approximately 3–5 minutes of accumulation capacity at full production rate, allowing the labeling machine to perform minor interventions (label roll changes, printer ribbon replacement) without forcing the assembly system to stop.

The mechanical interface between P2 and the labeling machine is designed for consistent pen orientation - ensuring that every pen arrives at the labeling station in the correct rotational position for label application. This eliminates the need for a separate orientation station on the labeling machine, simplifying the downstream equipment and reducing potential jam points.

 

For markets requiring serialization (EU FMD, US DSCSA), the final assembly system provides a data handshake with the downstream serialization system. The RFID-based traceability data from the assembly process - including the unique pallet/nest identification and all inspection results - can be linked to the serial number applied during labeling. This creates a complete digital thread from component assembly through to the serialized finished product, supporting full supply chain traceability requirements.

 

The communication interface between the assembly system and downstream equipment uses standard industrial protocols (OPC UA or Profinet), ensuring compatibility with labeling and packaging equipment from any major supplier.

DROFEN MACHINERY does not deliver final assembly equipment as a standalone machine. Unlike conventional equipment suppliers who receive component drawings from the customer and design tooling around fixed dimensions, DROFEN maintains an in-house injection pen device platform - including pen body industrial design, mold development, and component dimensional optimization. This vertical integration ensures that the components arriving at the final assembly line are dimensionally optimized for automated assembly from the outset, dramatically reducing the process development effort required during commissioning.

 

For customers who do not yet have a finalized pen body design, DROFEN can supply both the device platform and the automated assembly equipment as a single integrated package. This eliminates the multi-vendor coordination risk that frequently delays CDMO production line projects.

 

Typical Project Timeline:

When evaluating final assembly equipment, procurement teams frequently focus on the capital expenditure (CAPEX) comparison between competing suppliers. However, for final assembly specifically, the operational cost impact of rejection rate differences far exceeds the initial equipment price differential over the lifetime of the system.

 

Consider a final assembly line producing 80 pens per minute at an OEE of 85%, operating two shifts per day, 250 days per year. The annual output is approximately 16.3 million pens. If the drug cartridge cost is $6.00 per unit (a conservative estimate for GLP-1 formulations), the total annual drug value passing through the final assembly system is approximately $98 million.

 

At this scale, the difference between a 99.5% qualification rate and a 99.0% qualification rate is not trivial:

 

The difference between 99.5% and 99.0% - a mere half percentage point - represents nearly $500,000 in annual drug product loss. Over a typical 10-year equipment lifecycle, this single half-point difference accumulates to approximately $5 million in additional waste. This figure typically exceeds the total purchase price of the assembly equipment itself.

 

Rejection rate in final assembly is not primarily determined by machine speed or mechanical precision. The dominant factors are:

 

Integration quality between pre-assembly and final assembly: When the pen body components are manufactured and assembled by one supplier, but the final assembly equipment is designed by a different supplier, dimensional assumptions frequently conflict. A cartridge holder designed with nominal dimensions may not account for the actual statistical distribution of pen body internal diameters from a specific mold. These integration mismatches manifest as elevated force-displacement curve failures during the press-fit operation - not because the equipment is poorly designed, but because the component dimensions were not co-optimized with the assembly process.

 

Incoming component quality verification: A final assembly system without comprehensive incoming inspection will attempt to process non-conforming pen bodies - resulting in downstream failures at the press station or functional test. Each of these failures wastes a drug cartridge. Systems with robust incoming verification (LVDT baseline measurement, vision inspection, presence detection) reject non-conforming pen bodies before the cartridge is integrated - preserving the drug product for re-work or investigation.

 

Force monitoring sensitivity: Systems using simple peak-force-only monitoring will pass units with abnormal curve shapes (indicating potential defects) as long as the peak force falls within the acceptance window. These units may fail during patient use - creating field complaints and potential recalls. Conversely, systems with full force-displacement curve monitoring may initially show slightly higher rejection rates during commissioning, but these rejections represent genuine quality issues being correctly identified rather than false rejects.

 

The total cost of ownership calculation fundamentally changes the equipment selection decision. A system priced 20% higher than a competitor but delivering 0.5% better qualification rate will typically pay back the price premium within the first 12–18 months of operation - and continue generating savings for the remaining 8+ years of its lifecycle. Procurement teams evaluating final assembly equipment should request documented qualification rate data from FAT runs, and should weight this metric heavily in their supplier evaluation matrix.

Q: What is force-displacement curve monitoring in pen injector assembly and why is it important?

A: Force-displacement curve monitoring is the most critical quality assurance technology in pen injector final assembly. It uses a Kistler piezoelectric load cell (0–2000N range) combined with a Balluff linear displacement transducer to capture the complete force-versus-distance profile during the cartridge press-fit operation. Unlike simple peak-force testing - which only checks whether maximum force stays below a threshold - force-displacement curve monitoring evaluates the entire insertion stroke against a validated acceptance envelope. This detects subtle defects such as internal micro-cracks, injection molding flash, and incorrect component seating that peak-force methods would miss. At final assembly, where every rejected unit means the loss of a pre-filled drug cartridge worth $5–$10, this level of inspection sensitivity directly protects production economics.

 

Q: How do pen injector final assembly machines prevent defective products from reaching patients?

A: Pen injector final assembly machines prevent defective products through a multi-layered quality system. DROFEN's 24-station platform uses RFID-tracked pallets (42 pallets × 6 nests) to maintain unit-level traceability throughout the entire process. When any station detects a defect - whether through Kistler force monitoring, Keyence LVDT dimensional measurement, or vision inspection - the specific pallet nest is electronically flagged as "BAD." All subsequent stations read this flag and bypass the defective unit. The non-conforming part is automatically segregated at a dedicated reject station. Additionally, conservative event handling sets ALL parts currently in the system to BAD on any system fault (power failure, air loss, E-stop), ensuring no uncertain-quality product ever exits as finished goods. This approach achieves ≥ 99.5% assembly qualification rate while maintaining 100% inspection coverage.

 

Q: What is the best machine architecture for high-speed pen injector final assembly?

A: A modular 2-cell architecture with cam-driven material handling is the optimal design for high-speed pen injector final assembly at 80–160 pens per minute. DROFEN's platform divides the process into two cells of 12 stations each: Cell 1 handles pre-primming and component loading, Cell 2 handles cartridge integration and press-fit with Kistler force monitoring. This architecture enables parallel development and independent validation of each cell, isolates maintenance activities so one cell can be serviced without stopping the other, and delivers a compact cleanroom footprint. The cam-driven transport provides inherently repeatable motion paths at 42 cycles per minute without the servo tuning drift or encoder feedback issues that affect robotic alternatives over millions of cycles.

 

Q: Can one pen injector assembly line handle multiple drug products (insulin, GLP-1, combination therapies)?

A: Yes. DROFEN's pen injector final assembly platform accommodates multiple cartridge-based drug products through recipe-based changeover. The system supports 1.5 mL and 3.0 mL cartridge volumes covering insulin (daily dosing), GLP-1 receptor agonists (weekly dosing), and combination therapies. Each drug product variant has a validated recipe that defines pre-primming cycle count, Keyence LVDT acceptance ranges, Kistler force-displacement envelope boundaries, and press stroke distance. Mechanical changeover is minimal - the press station grippers switch via pneumatic slider cylinders - allowing variant transitions within a single production shift without manual tool changes.

 

Q: What are the risks of buying pen injector pre-assembly and final assembly equipment from different suppliers?

A: Buying pre-assembly and final assembly equipment from different suppliers creates an "integration gap" that typically increases rejection rates by 0.5–1.5 percentage points during commissioning. The root cause is dimensional mismatch: a cartridge holder designed with nominal dimensions by one supplier may not account for the actual statistical distribution of pen body internal diameters produced by another supplier's molds. These mismatches manifest as elevated force-displacement curve failures at the press-fit station - not because either machine is poorly designed, but because the component dimensions were never co-optimized. At $6 per cartridge, a 0.5% increase in rejection rate costs approximately $500,000 per year on a 16-million-unit line. DROFEN eliminates this risk through vertical integration - supplying both the pen body platform and the assembly equipment as a single coordinated system.

 

Q: How long does it take to commission a pen injector final assembly line, and what are the common challenges?

A: A complete pen injector final assembly line project typically takes 8–10 months from kick-off to production-ready SAT completion. The timeline includes: URS finalization (2–4 weeks), design and engineering (8–12 weeks), manufacturing (12–16 weeks), FAT at DROFEN's facility (4–6 weeks), shipping and installation (2–4 weeks), and SAT at the customer's site (4–6 weeks). The most common commissioning challenge is force-displacement curve optimization - establishing the correct Kistler acceptance envelope that balances defect detection sensitivity against false reject rate. This requires running statistically significant sample sizes across multiple component batches. DROFEN's approach of co-developing pen body components and assembly equipment reduces this optimization effort because component dimensional distributions are already characterized during mold qualification.

 

Q: How does a pen injector final assembly system handle GLP-1 weekly-dose pens versus daily-dose insulin pens?

A: GLP-1 weekly-dose pens and daily-dose insulin pens differ in cartridge volume (1.5 mL vs 3.0 mL), dosing mechanism travel range, and dose button force requirements. DROFEN's final assembly platform accommodates both through validated recipe management on the Siemens PLC and Advantech HMI. Each pen variant has a dedicated recipe controlling: 4-cycle pre-primming parameters, Keyence LVDT measurement acceptance ranges at all four checkpoints, Kistler force-displacement envelope boundaries, servo press speed and stroke distance, and vision inspection reference images. Recipe changes require supervisor-level access and are fully captured in the 21 CFR Part 11 compliant audit trail. The mechanical changeover between variants requires only a pneumatic slider cylinder position switch - no manual tool changes.

 

Q: What electronic batch record data does a pen injector assembly system provide for regulatory submission?

A: DROFEN's pen injector final assembly system generates comprehensive electronic batch records (EBR) compliant with FDA 21 CFR Part 11 and EU Annex 11. For each of the 84 pens produced per minute, the following data is recorded: complete Kistler force-displacement curve from the press-fit operation, all four Keyence LVDT dimensional measurements (incoming baseline, post-pre-primming, pre-press cartridge position, and final gap verification), vision inspection results with stored images, RFID pallet and nest identification, timestamp for every operation, operator identification, and any alarm or event during processing. The EBR is exported as a non-modifiable PDF for inclusion in batch release documentation. All records include a complete audit trail showing parameter changes, supporting both batch release decisions and post-market surveillance requirements.

DROFEN MACHINERY EQUIPMENT CO., LTD is a specialized system supplier focused on the critical intersection of aseptic filling and final device integration. Unlike general-purpose automation builders, DROFEN bridges the high-risk gap between pre-filled drug cartridges (PFS/cartridges) and complex delivery devices (injection pens/auto-injectors). By delivering integrated final assembly and fill-finish solutions, DROFEN eliminates the multi-vendor integration risks that typically delay product launches. The company partners with global CDMOs to deliver GMP-compliant, fully validated production lines that ensure zero-defect final assembly for high-value injectable therapies.

 

Published in: Pharmaceutical Technology (June 2026) - "Overcoming Fill-Finish Capacity Bottlenecks in Automated Pen Injector Assembly Lines"

Contact: www.drofen-pharma.com